Praxis Precision Medicines 

Yahoo Finance • 8 hours ago

Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor

FDA assigned PDUFA target action date of January 29, 2027 No advisory committee meeting expected BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous sy... Full story

Yahoo Finance • 20 days ago

Sarepta (SRPT) Skyrockets 35% on Morgan Stanley PT Hike, Stellar Trial Results

Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the 10 Stocks Investors Are Buying Now. Sarepta Therapeutics soared by 34.98 percent on Wednesday to finish at $23.77 apiece, as investors took path from Morgan Stanley’s 25-percent price... Full story

Yahoo Finance • 23 days ago

Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges

On February 17, 2026, B Group, Inc. disclosed a new position in Structure Therapeutics(NASDAQ:GPCR), acquiring 90,000 shares in the fourth quarter. What happened B Group disclosed in a Securities and Exchange Commission (SEC) filing date... Full story

Yahoo Finance • 29 days ago

Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch

Key Points Cormorant Asset Management established a new stake in Olema Pharmaceuticals, purchasing 2,750,000 shares in the fourth quarter. The value of the position was $68.75 million at quarter-end. The new position places Olema outside... Full story

Yahoo Finance • 30 days ago

A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?

On February 17, 2026, Logos Global Management LP disclosed in a Securities and Exchange Commission filing that it bought 1,100,000 shares of Immunovant(NASDAQ:IMVT), an estimated $24.53 million trade based on quarterly average pricing. Lo... Full story

Yahoo Finance • last month

This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision

Key Points Deerfield Management Company bought 418,538 Vera Therapeutics shares in the fourth quarter; the estimated trade size was $14.87 million. Meanwhile, the quarter-end position value rose by $99.77 million, reflecting both the new... Full story

Yahoo Finance • last month

Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline

On February 17, 2026, Deerfield Management Company disclosed a buy of Praxis Precision Medicines(NASDAQ:PRAX), adding 62,500 shares in a trade estimated at $11.64 million based on quarterly average pricing. What happened According to a f... Full story

Yahoo Finance • last month

This Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 Breakthrough

On February 17, 2026, Driehaus Capital Management disclosed a buy of Xenon Pharmaceuticals(NASDAQ:XENE), adding 369,577 shares in an estimated $15.52 million trade based on quarterly average pricing. What happened According to an SEC fil... Full story

Yahoo Finance • last month

Battery Storage Stock Up 50% in a Year Draws New $110M Investment. Here's What You Should Know

Driehaus Capital Management disclosed a significant buy of Eos Energy Enterprises(NASDAQ:EOSE) in its February 17, 2026, SEC filing, adding 7.70 million shares in an estimated $110.72 million trade based on quarterly average pricing. What... Full story

Yahoo Finance • last month

Zenas BioPharma, Inc. (ZBIO): A Bull Case Theory

We came across a bullish thesis on Zenas BioPharma, Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on ZBIO. Zenas BioPharma, Inc.'s share was trading at $27.02 as of February 19th. ZBIO’s trai... Full story

Yahoo Finance • 2 months ago

Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million

On February 17, 2026, Perceptive Advisors disclosed a significant buy of 431,432 shares of Praxis Precision Medicines(NASDAQ:PRAX), with an estimated transaction value of $80.34 million based on quarterly average pricing, according to its... Full story

Yahoo Finance • 2 months ago

Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position

On February 17, 2026, Perceptive Advisors reported a buy of Celcuity(NASDAQ:CELC), adding 203,881 shares in the fourth quarter, with an estimated transaction value of $16.76 million based on quarterly average pricing. What happened Accor... Full story

Yahoo Finance • 2 months ago

Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction

On February 17, 2026, Perceptive Advisors disclosed a buy of 978,662 shares of Apogee Therapeutics(NASDAQ:APGE), with an estimated transaction value of $61.64 million based on quarterly average pricing. What happened According to a Febru... Full story

Yahoo Finance • 2 months ago

$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges

Perceptive Advisors disclosed a sale of 1,002,282 Arcellx(NASDAQ:ACLX) shares in a February 17, 2026, SEC filing, with the estimated transaction value at $79.96 million based on quarterly average pricing. What happened According to a SEC... Full story

Yahoo Finance • 2 months ago

Wells Fargo Cautious on Praxis Precision (PRAX) After Recent Revenue Estimates

Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the 13 hot stocks to buy with the highest upside potential. On February 2, Wells Fargo gave a more tempered assessment on the stock, initiating coverage of the company with an Equal W... Full story

Yahoo Finance • 2 months ago

Guggenheim Raises Price Target for Praxis Precision Medicines (PRAX)

Praxis Precision Medicines (NASDAQ:PRAX) is one of the 17 biotechnology stocks with more than 50% upside. On February 10, Guggenheim analyst Yatin Suneja raised the price target on Praxis Precision Medicines (NASDAQ:PRAX) from $760 to $80... Full story

Yahoo Finance • 2 months ago

Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress

On February 13, 2026, Affinity Asset Advisors disclosed a new position in Praxis Precision Medicines(NASDAQ:PRAX), acquiring 185,000 shares in an estimated $54.53 million trade. What happened According to a SEC filing dated February 13,... Full story

Yahoo Finance • 2 months ago

Guggenheim Raises Target on Praxis Precision Medicines (PRAX) to $800

Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the 13 High-Risk High-Reward Growth Stocks to Invest In. Guggenheim, on February 10, raised its target price on Praxis Precision (PRAX) by 5.3% to $800 (from $760) and reiterated its... Full story

Yahoo Finance • 2 months ago

Soleus Adds a Significant Number of Celcuity Shares

Key Points Soleus increased its Celcuity stake by 629,398 shares. The firm held over 1.8 million shares at the end of the quarter. Celcuity now accounts for 6.7% of fund AUM10 stocks we like better than Celcuity › On Feb. 12, Soleus Capi... Full story

Yahoo Finance • 2 months ago

Exploring 3 High Growth Tech Stocks In The US Market

As February begins, the U.S. stock market has shown a robust start with major indices like the Dow Jones and S&P 500 posting significant gains, reflecting positive sentiment despite recent economic uncertainties such as delayed jobs report... Full story